<VariationArchive RecordType="classified" VariationID="11379" VariationName="NM_000061.3(BTK):c.1589del (p.Asn530fs)" VariationType="Deletion" Accession="VCV000011379" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-12-25" DateCreated="2018-11-03" MostRecentSubmission="2018-11-03">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="26418" VariationID="11379">
      <GeneList>
        <Gene Symbol="BTK" FullName="Bruton tyrosine kinase" GeneID="695" HGNC_ID="HGNC:1133" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101349450" stop="101390796" display_start="101349450" display_stop="101390796" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100604434" stop="100641211" display_start="100604434" display_stop="100641211" Strand="-" />
          </Location>
          <OMIM>300300</OMIM>
          <Haploinsufficiency last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BTK">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BTK">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000061.3(BTK):c.1589del (p.Asn530fs)</Name>
      <CanonicalSPDI>NC_000023.11:101354671:TTT:TT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101354672" stop="101354672" display_start="101354672" display_stop="101354672" variantLength="1" positionVCF="101354671" referenceAlleleVCF="GT" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100609660" stop="100609660" display_start="100609660" display_stop="100609660" variantLength="1" positionVCF="100609659" referenceAlleleVCF="GT" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>N354fs</ProteinChange>
      <ProteinChange>N530fs</ProteinChange>
      <ProteinChange>N564fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.100609662del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.100609662del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.101354674del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.101354674del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009616.1" sequenceAccession="NG_009616" sequenceVersion="1" change="g.36553del">
            <Expression>NG_009616.1:g.36553del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000061.3" sequenceAccession="NM_000061" sequenceVersion="3" change="c.1589del" MANESelect="true">
            <Expression>NM_000061.3:c.1589del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000052.1" sequenceAccession="NP_000052" sequenceVersion="1" change="p.Asn530fs">
            <Expression>NP_000052.1:p.Asn530fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287344.2" sequenceAccession="NM_001287344" sequenceVersion="2" change="c.1691del">
            <Expression>NM_001287344.2:c.1691del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001274273.1" sequenceAccession="NP_001274273" sequenceVersion="1" change="p.Asn564fs">
            <Expression>NP_001274273.1:p.Asn564fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287345.2" sequenceAccession="NM_001287345" sequenceVersion="2" change="c.1061del">
            <Expression>NM_001287345.2:c.1061del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001274274.1" sequenceAccession="NP_001274274" sequenceVersion="1" change="p.Asn354fs">
            <Expression>NP_001274274.1:p.Asn354fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_128" sequenceAccession="LRG_128">
            <Expression>LRG_128:g.36553del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="300300.0038" DB="OMIM" />
        <XRef Type="rs" ID="2147425836" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff provided an HGVS expression for allelic variant 300300.0038 from the sequence reported in Figure 3 of the paper by Hagemann et al., 1994 (PubMed 7880320).</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000061.3(BTK):c.1589del (p.Asn530fs) AND X-linked agammaglobulinemia" Accession="RCV000012132" Version="18">
        <ClassifiedConditionList TraitSetID="3110">
          <ClassifiedCondition DB="MedGen" ID="C0221026">X-linked agammaglobulinemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1994-10-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1994-10-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2018-11-03" MostRecentSubmission="2018-11-03">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">7880320</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3110" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="39" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Bruton-type agammaglobulinemia</ElementValue>
                <XRef ID="MONDO:0010421" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">X-linked agammaglobulinemia</ElementValue>
                <XRef ID="X-linked+agammaglobulinemia/7543" DB="Genetic Alliance" />
                <XRef ID="65880007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">AGAMMAGLOBULINEMIA, X-LINKED, TYPE 1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Agammaglobulinemia, Bruton tyrosine kinase</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Agammaglobulinemia, BTK</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">BTK-deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Bruton's agammaglobulinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">IMMUNODEFICIENCY 1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AGMX1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">IMD1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">XLA</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">X-linked agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in affected males in the first two years of life. Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. S pneumoniae and H influenzae are the most common organisms found prior to diagnosis and may continue to cause sinusitis and otitis after diagnosis and the initiation of gammaglobulin substitution therapy. Severe, difficult-to-treat enteroviral infections (often manifest as dermatomyositis or chronic meningoencephalitis) can be prevented by this treatment. The prognosis for individuals with XLA has improved markedly in the last 25 years as a result of earlier diagnosis, the development of preparations of gammaglobulin that allow normal concentrations of serum IgG to be achieved, and more liberal use of antibiotics.</Attribute>
                <XRef ID="NBK1453" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1033" />
                <XRef ID="1033" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301626</ID>
                <ID Source="BookShelf">NBK1453</ID>
              </Citation>
              <XRef ID="229717" DB="Orphanet" />
              <XRef ID="47" DB="Orphanet" />
              <XRef ID="C0221026" DB="MedGen" />
              <XRef ID="MONDO:0010421" DB="MONDO" />
              <XRef Type="MIM" ID="300755" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="32366" SubmissionDate="2018-10-29" DateLastUpdated="2018-11-03" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="300300.0038_AGAMMAGLOBULINEMIA, X-LINKED" title="BTK, 1-BP DEL, 1720A_AGAMMAGLOBULINEMIA, X-LINKED" />
        <ClinVarAccession Accession="SCV000032366" DateUpdated="2018-11-03" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1994-10-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with X-linked agammaglobulinemia (XLA; 300755), Hagemann et al. (1994) identified a 1-bp deletion (A1720) at codon 530 in exon 16, which is in the substrate specific portion of the SH1 domain in the BTK gene. This deletion results in a frameshift that generates a stop codon at nucleotide position 1796-1798 and eliminates the C-terminal portion of the catalytic domain.</Attribute>
              <Citation>
                <ID Source="PubMed">7880320</ID>
              </Citation>
              <XRef DB="OMIM" ID="300755" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BTK" />
          </GeneList>
          <Name>BTK, 1-BP DEL, 1720A</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DEL, 1720A</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="300300.0038" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">AGAMMAGLOBULINEMIA, X-LINKED</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="32366" TraitType="Disease" MappingType="Name" MappingValue="AGAMMAGLOBULINEMIA, X-LINKED" MappingRef="Preferred">
        <MedGen CUI="C0221026" Name="X-linked agammaglobulinemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

